Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Other Non-Current Liabilities (2019 - 2021)

Keros Therapeutics filings provide 3 years of Other Non-Current Liabilities readings, the most recent being $16000.0 for Q3 2021.

  • On a quarterly basis, Other Non-Current Liabilities fell 79.22% to $16000.0 in Q3 2021 year-over-year; TTM through Sep 2021 was $16000.0, a 79.22% decrease, with the full-year FY2020 number at $62000.0, down 47.9% from a year prior.
  • Other Non-Current Liabilities hit $16000.0 in Q3 2021 for Keros Therapeutics, down from $32000.0 in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $119000.0 in Q4 2019 to a low of $16000.0 in Q3 2021.
  • Median Other Non-Current Liabilities over the past 3 years was $69500.0 (2020), compared with a mean of $68500.0.
  • Biggest five-year swings in Other Non-Current Liabilities: plummeted 47.9% in 2020 and later crashed 79.22% in 2021.
  • Keros Therapeutics' Other Non-Current Liabilities stood at $119000.0 in 2019, then tumbled by 47.9% to $62000.0 in 2020, then tumbled by 74.19% to $16000.0 in 2021.
  • The last three reported values for Other Non-Current Liabilities were $16000.0 (Q3 2021), $32000.0 (Q2 2021), and $47000.0 (Q1 2021) per Business Quant data.